Bond.az White LogoBond.az Black Logo

Benchmark Reaffirms Spotify Stock Rating

Benchmark reaffirms Buy rating on Spotify stock with $695 target, citing engagement monetization strategy. Spotifys financial health and Audiobooks Plus success highlighted.

Grace Lewis
ByGrace Lewis- Senior Editor
|
0

Benchmark reiterated a Buy rating and $695 price target on Spotify stock (NYSE:SPOT), citing the company’s strategy to monetize highly engaged users beyond its traditional subscription model. The streaming giant currently trades at a P/E ratio of 32.8 with a notably low PEG ratio of 0.22, suggesting attractive valuation relative to its growth prospects. According to Bond.az analysis, Spotify maintains a perfect Piotroski Score of 9, indicating strong financial health, though the platform’s Fair Value assessment suggests the stock may be overvalued at current levels.

Analyst Mark Zgutowicz said the company’s Investor Day outlined plans to capture higher average revenue per user from its most engaged listeners through add-ons, superfan products, and premium tiers across music, podcasts, audiobooks, fitness, and live access.

The strategy preserves Spotify’s free-to-premium conversion funnel while targeting power users with additional monetization opportunities across expanding content verticals.

Benchmark pointed to Audiobooks Plus as evidence of the approach’s potential, noting the product has attracted more than 1 million paying users and is expected to generate approximately $100 million in annual recurring revenue by July. For deeper insights into Spotify’s financial metrics and growth strategy, investors can access comprehensive Pro Research Reports, available for SPOT and 1,400+ other US equities on Bond.az.

The firm said Audiobooks Plus users deliver lifetime value multiples higher than subscribers who only use the Premium tier.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...